On May 29, 2013, Anacor Pharmaceuticals (NASDAQ:ANAC) announced successful completion of pre-NDA (New Drug Application) communication with the United States Food and Drug Administration (FDA) related to tavaborole, Anacor's lead drug candidate for the treatment of onychomycosis. More recently, on July 26, 2013, Anacor indicated that it had submitted its NDA to the FDA. The FDA has sixty days to decide whether to accept this NDA for review. Based on analysis of scientific literature and clinical data on drug efficacy and safety, we believe the NDA for tavaborole will be accepted for review and will then be approved by mid-2014.
Anacor is a biopharmaceutical company with eight drug candidates in its pipeline. Its lead product candidates include...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|